Prokidney and social capital suvretta holdings corp. iii (“scs”) to host analyst and investor day on april 28, 2022

Winston-salem, n.c., april 18, 2022 (globe newswire) -- prokidney lp (prokidney) is a leading phase 3 clinical-stage cellular therapeutics company with regenerative medicine advanced therapy (rmat) designation that has the goal of delaying chronic kidney disease (ckd), preventing end-stage renal disease (esrd), and preventing the need for dialysis. social capital suvretta holdings corp. iii (scs) (nasdaq: dnac), is a special purpose acquisition company. prokidney and scs today announced that they will host an analyst and investor day in new york on thursday, april 28, 2022, beginning at 8:00 a.m. et.
PROK Ratings Summary
PROK Quant Ranking